Thus, our findings indicate that targeting cytolytic CD8+ T cells driven by hypoxic microenvironments will improve the prognosis for patients with cutaneous leishmaniasis and other inflammatory skin diseases. This evidence concerns the gene CD8A and cutaneous leishmaniasis.